[an error occurred while processing this directive]
血管通路

经隧道式中心静脉导管行血液透析导管相关血流感染发病率及危险因素的系统评价与Meta分析

  • 豆欣蔓 ,
  • 谢琪 ,
  • 张丽红 ,
  • 钟娟平 ,
  • 王兴蕾
展开
  • 730000 兰州,兰州大学第二医院1护理部 3神经内科 4肝病科
    730000 兰州,2兰州大学护理学院

收稿日期: 2022-12-02

  修回日期: 2023-01-11

  网络出版日期: 2023-03-03

基金资助

甘肃省2022年度省社科规划一般项目;2020年甘肃省省级科技计划(重点研发计划)

Incidence and risk factors for catheter-related bloodstream infections in hemodialysis through tunneled central venous catheters: a systematic review and meta-analysis

  • DOU Xin-Man ,
  • XIE Qi ,
  • ZHANG Li-Hong ,
  • ZHONG Juan-Ping ,
  • WANG Xing-Lei
Expand
  • Department of Nursing, 3Department of Neurology, and 4Department of Liver Diseases Branch, Lanzhou University Second Hospital, Lanzhou 730000, China; 2School of Nursing, Lanzhou University, Lanzhou 730000, China

Received date: 2022-12-02

  Revised date: 2023-01-11

  Online published: 2023-03-03

Supported by

甘肃省哲学社会科学规划项目阶段性研究成果(2022YB154);2020年甘肃省省级科技计划(重点研发计划)(20YF8FA077)

摘要

目的 系统评价经隧道式中心静脉导管行血液透析导管相关血流感染(catheter-related blood stream infection,CRBSI)发病率及危险因素。方法 检索从建库到2022年9月PubMed、Web of science、Embase、Cochrane Library、中国知网、维普、万方和中国生物医学文献数据库,搜集报道了CRBSI发病率和/或危险因素的临床研究。采用R语言(version 4.1.2)进行单组率和危险因素的Meta分析。 结果 共纳入21篇文献,6758例经隧道式中心静脉导管行血液透析的患者。Meta分析结果显示:CRBSI总发病率为14.5%,欧洲人群发病率为28.9%(95% CI:16.2%~43.5%),病例对照研究的发病率为26.3%(95% CI:14.1%~40.7%),年龄≥60岁人群发病率为22.2%(95%CI:14.5%~31.0%),导管使用时间>24个月的发病率为28.2%(95% CI:2.5%~67.2%)。年龄≥60岁(OR=1.85,95% CI:1.29~2.64)、白蛋白<30g/L(OR=2.12,95% CI:1.40~3.22)、股静脉置管(OR=2.17,95% CI:1.24~3.80)、合并糖尿病(OR=1.82,95% CI:1.37~2.40)、置管时间≥4周(OR=2.04,95% CI:1.22~3.41)是经隧道式中心静脉导管行血液透析患者发生CRBSI的重要危险因素。结论 经隧道式中心静脉导管行血液透析CRBSI发生率较高,年龄≥60岁、白蛋白<30g/L、股静脉置管、合并糖尿病、置管时间≥4周是CRBSI的重要危险因素。

本文引用格式

豆欣蔓 , 谢琪 , 张丽红 , 钟娟平 , 王兴蕾 . 经隧道式中心静脉导管行血液透析导管相关血流感染发病率及危险因素的系统评价与Meta分析[J]. 中国血液净化, 2023 , 22(03) : 214 -220 . DOI: 10.3969/j.issn.1671-4091.2023.03.013

Abstract

Objective To systematically review the incidence and risk factors for catheter-related bloodstream infection (CRBSI) in hemodialysis patients undergoing tunneled central venous catheterization.  Methods  PubMed, Web of science, Embase, Cochrane Library, CBM, WanFang Data, VIP and CNKI databases from the establishment of the database to September 2022 were searched for clinical studies about the incidence and/or risk factors of CRBSI. R software (version 4.1.2) was used for meta-analysis of single-group rate and risk factors.  Results   A total of 21 studies were included, including 6,758 patients undergoing hemodialysis through tunneled central venous catheters. Meta-analysis showed that the pooled incidence of CRBSI was 14.5%, the incidence was 28.9% in European population (95% CI:16.2%~43.5%), and the incidence was 26.3% from case-control study (95% CI:14.1%~40.7%). The incidence was 22.2% (95% CI:14.5%, 31.0%) in patients aged≥60 years, and 28.2% (95% CI:2.5%~67.2%) in patients with catheterization duration of >24 months. Age≥60 years old (OR=1.85, 95% CI:1.29~2.64), albumin <30g/L (OR=2.12, 95% CI:1.40~3.22), femoral vein catheterization (OR=2.17, 95% CI:1.24~3.80), diabetes mellitus (OR=1.82, 95% CI:1.37~2.40), and catheterization period≥4 weeks (OR=2.04, 95% CI:1.22~3.41) were the important risk factors for CRBSI in hemodialysis patients undergoing tunneled central venous catheterization.  Conclusion The incidence of CRBSI is higher in patients undergoing hemodialysis through tunneled central venous catheter. Age≥60 years, albumin <30g/L, femoral vein catheterization, diabetes mellitus, catheterization period≥4 weeks are the important risk factors for CRBSI.

参考文献

[1]SHEN J I, WINKELMAYER W C.Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, 60(3):473-86 [2]方帆, 杜晓刚.尿毒症患者导管相关性血流感染的危险因素分析[J].中国血液净化, 2017, 16(06):423-6 [3]KOSA S D, AL-JAISHI A A, MOIST L, et al.Preoperative vascular access evaluation for haemodialysis patients[J].The Cochrane database of systematic reviews, 2015, 2015(9):C-d007013 [4]Moist L M, Lok C E, Vachharajani T J, et al.Optimal hemodialysis vascular access in the elderly patient[J].Seminars in dialysis. Oxford, UK: Blackwell Publishing Ltd, 2012, 25(6):640-648 [5]VAN DEN BOSCH C H, JEREMIASSE B, VAN DER BRUGGEN J T, et al.The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis[J]. The Journal of hospital infection, 2022, 123: 143-55. [6]GOUDIE A, DYNAN L, BRADY P W, et al.Attributable cost and length of stay for central line-associated bloodstream infections[J].Pediatrics, 2014, 133(6):e1525-32 [7]KAYE K S, MARCHAIM D, CHEN T Y, et al.Effect of nosocomial bloodstream infections on mortality,length of stay,and hospital costs in older adults[J].Journal of the American Geriatrics Society, 2014, 62(2):306-11 [8]STEVENS V, GEIGER K, CONCANNON C, et al.Inpatient costs,mortality and 30-day re-admission in patients with central-line-associated bloodstream infections[J].Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014, 20(5):O318-24 [9]STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].European journal of epidemiology, 2010, 25(9):603-5 [10]AHRQ Methods for Effective Health Care [M].Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD); Agency for Healthcare Research and Quality (US). 2008. [11]刘亚敏, 赵培翔, 王宇飞, 等.透析导管相关血流感染的危险因素及风险预测模型[J].中华肾脏病杂志, 2022, 38(1):23-8 [12]赵明生, 陈远岷, 左晓英, 等.使用中心静脉导管行血液透析患者导管相关性血流感染的危险因素分析[J].中国医学前沿杂志电子版, 2021, 13(9):104-7 [13]丁少楠.例维持性血液透析患者导管相关血流感染及病原菌的分布及其防治对策[J].抗感染药学, 2020, 17(12):1783-6 [14]白亚飞, 陈汝满, 徐明芝.血液透析带隧道带涤纶套导管更换原因及并发症处理研究[J].临床肾脏病杂志, 2020, 20(1):30-5 [15]MARSENIC O, RODEAN J, RICHARDSON T, et al.Tunneled hemodialysis catheter care practices and blood stream infection rate in children: results from the SCOPE collaborative[J].PEDIATRIC NEPHROLOGY, 2020, 35(1):135-43 [16]POINEN K, QUINN R R, CLARKE A, et al.Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019, 73(4):467-75 [17]KRISHNAN A, IRANI K, SWAMINATHAN R, et al.A retrospective study of tunnelled haemodialysis central line-associated bloodstream infections[J].Journal of Chemotherapy, 2019, 31(3):132-6 [18]HOGGARD J G, BLAIR R D, MONTERO M, et al.Clinical outcomes associated with the use of the NexSite hemodialysis catheter with new exit barrier technology: Results from a prospective,observational multi-center registry study[J].PloS one, 2019, 14(10):e0223285- [19]GUILLERMO-CORPUS G, RAMOS-GORDILLO J M, PE?A-RODRíGUEZ J C.Survival and Clinical Outcomes of Tunneled Central Jugular and Femoral Catheters in Prevalent Hemodialysis Patients[J].Blood purification, 2019, 47(1-3):132-9 [20]周建芳 黄 A 应 A.血液透析带涤纶套中心静脉留置导管相关性血流感染的影响因素分析[J]. 中国中西医结合肾病杂志, 2017, 18(2). [21]邱丽, 姜斌, 肖剑.血透用中心静脉置管相关性感染的临床研究[J].中国中西医结合肾病杂志, 2016, 17(1):58-9 [22]WANG P, WANG Y, QIAO Y, et al.A Retrospective Study of Preferable Alternative Route to Right Internal Jugular Vein for Placing Tunneled Dialysis Catheters: Right External Jugular Vein versus Left Internal Jugular Vein[J].PloS one, 2016, 11(1):e0146411- [23]高姗, 文建国, 林江, 等.美国国家医疗安全网血液透析事件监测方法实践与数据分析[J].国际移植与血液净化杂志, 2015, 13(1):27-31 [24]MUREA M, JAMES K M, RUSSELL G B, et al.Risk of catheter-related bloodstream infection in elderly patients on hemodialysis[J].Clinical journal of the American Society of Nephrology : CJASN, 2014, 9(4):764-70 [25]MANDOLFO S, ACCONCIA P, BUCCI R, et al.Hemodialysis tunneled central venous catheters: five-year outcome analysis[J].The journal of vascular access, 2014, 15(6):461-5 [26]BRA?AS P, MORALES E, RíOS F, et al.Usefulness of endoluminal catheter colonization surveillance cultures to reduce catheter-related bloodstream infections in hemodialysis[J].American journal of infection control, 2014, 42(11):1182-7 [27]FYSARAKI M, SAMONIS G, VALACHIS A, et al.Incidence,clinical,microbiological features and outcome of bloodstream infections in patients undergoing hemodialysis[J].Int J Med Sci, 2013, 10(12):1632-8 [28]郑洁, 黄雯, 姜立萍.老年透析患者隧道式中心静脉置管相关血流感染临床分析[J].北京医学, 2012, 34(04):295-8 [29]THOMSON P, STIRLING C, TRAYNOR J, et al.A prospective observational study of catheter-related bacteraemia and thrombosis in a haemodialysis cohort: Univariate and multivariate analyses of risk association[J].Nephrology Dialysis Transplantation, 2010, 25(5):1596-604 [30]魏乐 石 A 徐 A 梁 A.血液透析患者中心静脉留置导管失功原因与处理[J]. 中国血液净化, 2009, (6). [31]MAZONAKIS E, STIRLING C, BOOTH K L, et al.The influence of comorbidity on the risk of access-related bacteremia in chronic hemodialysis patients[J].Hemodialysis international International Symposium on Home Hemodialysis, 2009, 13(1):6-10 [32]鲁华鹏, 马梅, 何晴, 等.中等长度导管及经外周静脉穿刺中心静脉置管导管相关血流感染发生率的分析[J].中国感染控制杂志, 2021, 20(4):309-19 [33]甘晓, 应燕萍, 蒋庆娟, 等.成人家庭肠外营养患者导管相关血流感染发病率的分析[J].中国感染控制杂志, 2020, 19(6):518-25 [34]GROTHE C, DA SILVA BELASCO A G, DE CáSSIA BITTENCOURT A R, et al.Incidence of bloodstream infection among patients on hemodialysis by central venous catheter[J].Revista latino-americana de enfermagem, 2010, 18(1):73-80 [35]林丽玉, 许丽春, 张鑫.血液透析患者中心静脉导管发生相关血流感染危险因素的分析[J].中华护理杂志, 2021, 56(10):1478-84 [36]JOHNS T S, MOKRZYCKI M H.Optimal Approach for the Diagnosis of Hemodialysis Catheter-Related Bacteremia[J].Clinical journal of the American Society of Nephrology : CJASN, 2016, 11(5):756-8 [37]金其庄, 王玉柱, 叶朝阳, 等.中国血液透析用血管通路专家共识第版[J].中国血液净化, 2019, 18(06):365-81 [38]何华平, 祝建辉, 鲍晓荣.透析用导管相关性感染易感因素探讨[J]. 中国临床医学, 2005, (05): 839-41. [39]岳晓红, 王晓星, 王沛, 等.血液透析患者中心静脉导管感染的危险因素[J].国际移植与血液净化杂志, 2017, 15(03):30-3 [40]黄春香, 黄丽华, 邢美园.口服营养补充对血液透析营养不良患者营养评价指标影响的分析[J].中华护理杂志, 2015, 50(12):1425-31 [41]施素华, 王培莉, 邹琼芳.互联网+”营养教育在维持性血液透析患者中的应用[J].中华护理杂志, 2021, 56(01):33-9 [42]赵林芳, 曾旭芬, 王雅萍.经大腿中段股静脉留置在例患者中的应用[J].中华护理杂志, 2018, 53(09):1089-92 [43]张丽红, 王自强, 段青青, 等.血液透析患者中心静脉阻塞性疾病的介入治疗[J]. 中华肾脏病杂志, 2011, (10): 781-2.[J].中华肾脏病杂志, 2011, 10:781-782
文章导航

/

[an error occurred while processing this directive]